Dr. Alan Sandler, from the Oregon Health & Science University, Discusses the Tivantinib Mechanism of Action
OncLive TV
Dr. Diane Bodurka, from the MD Anderson Cancer Center, on the Increasing Number of Cancer Surivors
Advertisement
Dr. Suzanne Topalian, from the Johns Hopkins University School of Medicine, on the PD-1 Targeted Immunotherapy BMS-936558.
Kathleen Madden, from NYU Langone Medical Center, on the Importance Educating Patients About Ipilimumab's Side Effects.
Dr. Richard Schilsky, from the University of Chicago, Summarizes the Recent Oncology Drug Shortage.
Dr. George Demetri, from Dana-Farber Cancer Institute, Explains the Side Effects Associated With Regorafenib.
Advertisement
Dr. David Gandara, from UC Davis Cancer Center, on Thymidylate Synthase Expression in ALK-Positive Non-small Cell Lung Cancer
Dr. Dirk Arnold, from the University Cancer Center Hamburg, Germany, on Second-Line Bevacizumab Continuation Therapy for Metastatic Colorectal Cancer
Dr. Charles Ryan, from UCSF Helen Diller Family Comprehensive Cancer Center, Discusses Sequencing Castration-Resistant Prostate Cancer Therapies.
Dr. Mark Kris, from Memorial Sloan-Kettering Cancer Center, Discusses Lung Cancer Information Presented at the 2012 ASCO Annual Meeting.
Dr. Bernard Escudier, from the Institut Gustave Roussy, on Patients Preferring Pazopanib for Metastatic Renal Cell Carcinoma.
Dr. Jorge Cortes, from the MD Anderson Cancer Center, Discusses the Ponatinib Ph+All and CML Evaluation (PACE) Trial
Dr. Raoul Concepcion, from the Urology Associates, PC, Nashville, TN, on Bladder Cancer Treatment and Costs.
Dr. Ezra Cohen, from the University of Chicago, Discusses the Cabozantinib (XL184) EXAM Trial
Dr. Alex Adjei, from Roswell Park Cancer Institute, on the Need for Targeted Therapy Education
Dr. Charles Ryan, from the UCSF Diller Family Comprehensive Cancer Center, on the COU-AA-302 Abiraterone Acetate Interim Analysis Results.
Dr. José Baselga, from Massachusetts General Hospital, on combining pertuzumab with trastuzumab
Dr. Neal Shore, from the Atlantic Urology Clinics, Discusses the Enzalutamide (MDV3100) AFFIRM Trial
Dr. Mary-Ellen Taplin, from Dana-Farber Cancer Institute, on Neoadjuvant Abiraterone Acetate and Leuprolide Acetate
Dr. Julie Brahmer, from the Sidney Kimmel Comprehensive Cancer Center, on the PD-1 Immunotherapy BMS-93655 Clinical Trial
Dr. Eric Larsen, from the Maine Children's Cancer Program, Discusses Outcomes for AYA Patients With Acute Lymphoblastic Leukemia
Dr. Raoul Concepcion, from Urology Associates, PC, Nashville, TN, Discusses New Prostate Cancer Therapies.
Dr. Maurie Markman, from Cancer Treatment Centers of America, on Awareness of Long-Term Chemotherapy Side Effects
Dr. Paul Sieber, from the Urological Association of Lancaster, on Managing Bone Health After the Introduction of ADT.
Krista Rubin, from Massachusetts General Hospital Cancer Center, on Understanding Ipilimumab's Toxicities.
Dr. Nancy Davidson, from the University of Pittsburgh Cancer Institute, on Screening for Ovarian Cancer
Dr. Leonard Gomella, form the Jefferson Kimmel Cancer Center, on the Impact of the New USPSTF PSA Rating.
Dr. Oliver Sartor, from Tulane Cancer Center, Discusses Prostate-Specific Antigen (PSA) Screening
Dr. Leonard Gomella, from the Jefferson Kimmel Cancer Center, on the Provenge IMPACT Trial Survival Benefit
Dr. Andrew Goy, from John Theurer Cancer Center, on Neoadjuvant Hormonal Therapy Plus Zytiga
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5